Pfizer (PFE) : Traders are bullish on Pfizer (PFE) as it has outperformed the S&P 500 by a wide margin of 2.95% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.8% in the last 1 week, and is up 7.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.39% and the 50-Day Moving Average is 6.41%.
Pfizer (NYSE:PFE): The stock opened at $36.97 on Friday but the bulls could not build on the opening and the stock topped out at $37.19 for the day. The stock traded down to $36.63 during the day, due to lack of any buying support eventually closed down at $36.77 with a loss of -0.41% for the day. The stock had closed at $36.92 on the previous day. The total traded volume was 25,090,491 shares.
The company Insiders own 0.07% of Pfizer shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.54% . Institutional Investors own 75.09% of Pfizer shares. During last six month period, the net percent change held by insiders has seen a change of -18.54%. In a related news, Damelio Frank A, officer (Executive Vice President) of Pfizer Inc, unloaded 100,000 shares at an average price of $34.49 on May 26, 2016. The total amount of the transaction was worth $3,449,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.